- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00797823
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
A Comparison of Two Sensor-Augmented Glycemic Control Systems in Persons With Type 1 Diabetes Mellitus: Subcutaneous (SC) Insulin and Glucagon Delivery vs. SC Insulin Only
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of the current human study is to compare glycemic control in persons with Type 1 Diabetes using the FMPD Insulin plus Glucagon Delivery Algorithm vs. the FMPD Insulin-Alone Algorithm. Subjects will undergo two 28-hour sensor-augmented glycemic control studies. Each subject will be fitted with two short term continuous glucose monitoring systems and two subcutaneous (SC) infusion catheters. These catheters will allow for SC delivery of insulin and glucagon (or insulin plus a glucagon placebo). The accuracy of the wire sensors will be verified every 10 minutes with a venous blood glucose test. For the first 4 hours, the insulin and glucagon delivery will be controlled by venous blood in order to assess and compare the accuracy of the two sensors, after which the more accurate sensor (if it remains accurate) will control the FMPD algorithm. The main outcomes of our study are time spent in the target range (70 - 180 mg/dl) and the percentage of studies requiring intervention due to hypoglycemia (glucose < 70 mg/dl). The accuracy of the sensors over the life of the study will also be evaluated.
The specific system used in this study of frequent blood testing and the use of two separate infusion pumps is not feasible for every day use for individuals with diabetes. However, if the glucose control algorithm (with or without the use of glucagon) provides effective blood glucose management over long time periods the calculation program may be integrated into a continuous blood glucose monitoring system with an insulin and glucagon pump.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97232
- Legacy Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 21-65, history of Type 1 Diabetes Mellitus for > 3 months.
Women:
- For women of childbearing potential, a negative urine pregnancy test is required on the first day of the study prior to sensor insertion AND the subject must agree to use contraception prior to and during the study.
- For menopausal women or those who have undergone surgical sterilization, no pregnancy test or contraception will be required.
- Willingness to attend all clinic visits and participate in two 28-hour studies or one 9-hour study.
- Hemoglobin A1C of 5.0-10%. (Values below 5.0 suggest a severe tendency towards hypoglycemia, and values above 10% suggest severely uncontrolled diabetes with risk for ketoacidosis.)
- Body mass index of 19-35.
Exclusion Criteria:
- Pregnancy, lactation or refusal to use contraception.
- Use of any investigational drug during the 30 days prior to screening.
- Enrollment or participation in any other research studies 30 days prior to and during the entirety of sensor insertion.
- Current alcohol abuse, substance abuse, or severe mental illness (as judged by the Principal Investigator (PI)).
- Any prior cerebrovascular accident or major permanent neurological damage such as aphasia, hemiparesis, or dementia.
- A history of cerebrovascular disease or cardiovascular disease regardless of the time since occurrence.
- Coronary artery disease (symptomatic or asymptomatic) as manifested by unstable angina, acute coronary syndrome, myocardial infarction or therapeutic coronary procedure (e.g., Percutaneous Transluminal Coronary Angioplasty (PTCA), stent placement, Coronary Artery By-pass Grafting (CABG)) within the prior 6 months.
- Any degree of heart failure (as defined by New York Heart Association)..
- Renal insufficiency (serum creatinine of > 2.5).
- Current foot or leg ulceration.
- Peripheral arterial disease with uncontrolled claudication.
- Active uncontrolled malignancy except basal cell or squamous cell skin cancers.
- Concurrent illness, other than diabetic mellitus, that is not controlled by a stable therapeutic regimen.
- Hemoglobin A1C of less than 5.0 or greater than 10%.
- A total bilirubin level above 1.5 mg/dl.
- Medications: Oral or parenteral corticosteroids (glucocorticoid therapy) are exclusions; topical corticosteroids are not.
- Any chronic immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
- Visual impairment that would prevent reading the display of the Medtronic Guardian® Receiver.
- Physical impairment that would prevent using the buttons of the Medtronic Guardian® Receiver.
- Serum Alanine Transaminase (ALT) or Aspartate Transaminase (AST) ≥3x the upper limit of normal.
- Serum albumin level of < 3.2 g/dl.
- Severe anemia as defined by a hematocrit of < 28%.
- Severe serum electrolyte abnormality (sodium, potassium, carbon dioxide, chloride).
- Cardiac rhythm disturbance characterized by: 2nd or 3rd degree heart block, bradycardia of less than 50 bpm (exception of bradycardia in an aerobic athlete), tachycardia of greater than 100 bpm, or any arrhythmia judged by the investigator to be exclusionary.
- A history of Human Immunodeficiency Virus (HIV) infection.
- An active hepatitis infection.
- Known allergy to any type of insulin
- Insulin resistance requiring more than 200 units of insulin per day
- Known bleeding disorders or chronic usage of warfarin.
- Any known seizure disorder.
- Past history of pheochromocytoma or a family history of Multiple Endocrine Neoplasia (MEN) 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease.
- Hypoglycemic unawareness or chronic hypoglycemia.
- A severe hypoglycemic event which required hospitalization within the past two years.
- Adrenal insufficiency.
- Insulinoma.
- Use of both acetaminophen and ascorbic acid.
- Impaired mentation or psychiatric diagnoses
- Uncontrolled candidiasis.
- Any known allergy to glucagon.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Insulin + Placebo
Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.
|
Saline solution 0.9%
Other Names:
Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
Other Names:
|
Active Comparator: Insulin + Glucagon
Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.
|
Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
Other Names:
During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia.
Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
Other Names:
|
Experimental: Pilot Study
Pilot studies designed to assess safety of the system.
Includes 6 participants undergoing 7 studies.
|
Saline solution 0.9%
Other Names:
Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
Other Names:
During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia.
Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of Closed Loop Diabetes Control
Time Frame: 1 year
|
Effectiveness of closed loop diabetes control will be measured by mean glucose.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent of Time Venous Blood Glucose <70 mg/dl
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William K. Ward, MD, Legacy Health System
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Insulin
- Insulin, Globin Zinc
- Glucagon
Other Study ID Numbers
- IRB4311
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States